Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan

by Zacks Equity Research

Aerie Pharmaceuticals, (AERI) announced that it has commenced phase III study -Mercury 3 in Europe for its pipeline candidate Roclatan 0.02%/0.005%.

    Allergan (AGN) Down 8.3% Since Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Allergan (AGN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Arpita Dutt headshot

      Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update

      by Arpita Dutt

      It was a landmark week for the pharmaceutical sector and the medical community with the FDA approving Novartis' (NVS) Kymriah, the first CAR-T cell treatment to be approved in the United States.

        The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins

          Will Conatus Key Candidate Emricasan Drive Long-Term Growth?

          by Zacks Equity Research

          Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.

            Shire Files Marketing Application for Lifitegrast in Europe

            by Zacks Equity Research

            Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

              Are Amgen's New Drugs Doing Well Enough to Drive Sales?

              by Zacks Equity Research

              Higher volumes of Amgen, Inc.'s (AMGN) new products may not be enough to offset the lost sales due to the decline in mature brands.

                Ryan McQueeney headshot

                Teva Plunges to 10-Year Low, Credit Rating in Jeopardy

                by Ryan McQueeney

                Shares of Teva Pharmaceuticals (TEVA), a favorite for investors chasing large dividend yields, fell more than 4.4%--and hit a 10-year intraday low--on Wednesday.

                  Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

                  by Zacks Equity Research

                  Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.

                    Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps

                    by Zacks Equity Research

                    Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.

                      Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down

                      by Zacks Equity Research

                      Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.

                        Allergan (AGN) Beats Q2 Earnings & Sales; Shares Down

                        by Zacks Equity Research

                        Allergan plc (AGN) beat expectations for both earnings and sales in the second quarter. However, shares declined in pre-market trading.

                          Tracey Ryniec headshot

                          5 Stocks that are Earnings All-Stars

                          by Tracey Ryniec

                          These companies have perfect, or near perfect, earnings surprise records over the last 5 years.

                            Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2

                            by Zacks Equity Research

                            Aerie Pharmaceuticals, Inc.'s (AERI) narrower-than-expected loss in the second quarter was encouraging.

                              Allergan (AGN) to Report Q2 Earnings: What's in the Cards?

                              by Zacks Equity Research

                              While Allergan plc's (AGN) Q2 sales are likely to be driven by new as well as established products and international growth, earnings will likely be driven by sales growth and cost control.

                                Paratek Antibiotic Candidate's Phase III Data Favorable

                                by Zacks Equity Research

                                Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

                                  Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod

                                  by Zacks Equity Research

                                  Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug Herceptin (trastuzumab).

                                    Allergan Reports Positive New Data on Irritable Bowl Drug

                                    by Zacks Equity Research

                                    Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel syndrome with diarrhea (IBS-D).

                                      Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK

                                      by Zacks Equity Research

                                      Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).

                                        Alkermes Presents Phase III Data on Schizophrenia Candidate

                                        by Zacks Equity Research

                                        Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.

                                          Sarepta Appoints Ex-Allergan Executive as CEO and President

                                          by Zacks Equity Research

                                          Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

                                            Allergan Continues to Focus on Acquisitions and Branded Unit

                                            by Zacks Equity Research

                                            We issued an updated research report on Allergan plc (AGN) on Jun 23.

                                              5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017

                                              by Zacks Equity Research

                                              London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.

                                                Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit

                                                by Zacks Equity Research

                                                Allergan plc (AGN) announced a deal to acquire privately held medical device company Keller Medical, Inc, which makes Keller Funnel, for an undisclosed amount.

                                                  Alkermes Gets FDA Nod for Two Month Dose of Aristada

                                                  by Zacks Equity Research

                                                  Alkermes plc (ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.